Synthetic Conjugated Estrogens, B

Summary

Synthetic Conjugated Estrogens, B (CHEMBL1201467) is an approved unknown; indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201467
Name	Synthetic Conjugated Estrogens, B
Type	Unknown
Max phase	4

Also known as: CE-10, Enjuvia, Estrogens, conjugated synthetic b, Synthetic conjugated estrogens, b, SYNTHETIC CONJUGATED ESTROGENS, B

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00196378	PHASE3	COMPLETED	A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).